Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia

This study has been completed.
Sponsor:
Collaborators:
National Institute of Mental Health (NIMH)
Ortho-McNeil Janssen Scientific Affairs, LLC
Information provided by (Responsible Party):
Keith Nuechterlein, Ph.D., University of California, Los Angeles
ClinicalTrials.gov Identifier:
NCT00330551
First received: May 26, 2006
Last updated: November 2, 2013
Last verified: November 2013